Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for HFpEF
NCT05126836Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Cilostazol First with Placebo First (2 arms). Primary endpoint: Kansas City Cardiomyopathy Questionnaire-12 at 4 weeks. Started Sep 2021; status: completed.
02
Drugs
cilostazol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05126836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126836.